Amplia Therapeutics Ltd - Amplia Therapeutics Undertakes Placement
Amplia Therapeutics Ltd (ASX:ATX)

Amplia Therapeutics Undertakes Placement

Published Jan 20, 2020

What happened?


What's happened?

Amplia Therapeutics Limtied (ASX:ATX) have undertaken a capital raising.

What are the key highlights?

  1. $0.93 million raised.
  2. Platinum International Healthcare Fund participated in the placement which was managed by Taylor Collison.
  3. The new capital will enable the Company to complete the clinic-enabling studies. The Company remains on track to initiate clinical trials of its lead FAK inhibitor, AMP945, during 2020.

CEO's summary

John Lambert CEO of Amplia Therapeutics Ltd has provided a statement.
John Lambert
John Lambert
CEO, Amplia Therapeutics Ltd

"We are delighted to have completed this placement as it will allow us to drive our FAK assets into the clinic. We are particularly pleased to see the participation in the placement of such highly regarded investors as Platinum and see this as a strong endorsement of the potential of Amplia’s FAK assets and the team we have put in place."

Download Announcement

View this announcement as well as our full profile on the company.

Comments

Share your thoughts about this announcement...

Similar articles
Amplia Receives Human Research Ethics Committee Clearance to Conduct Phase 1 Clinical Trial
What's happened? Amplia Therapeutics Limited (ASX: ATX, "Amplia") has received clearance from the Alfred Hospi...
3 years ago
Amplia Appoints Dr Mark Devlin as Chief Scientific Officer
What's happened? Amplia Therapeutics Limited (ASX: ATX, "Amplia") has announced that it has appointed Dr. Mark...
3 years ago
Amplia Appoints Nucleus Network to Conduct Phase 1 Clinical Trial
What's happened? Amplia Therapeutics Limited (ASX: ATX) has appointed the Nucleus Network in Melbourne to conduct its up...
3 years ago
Around the web
Amplia Therapeutics updates on next stage of ACCENT pancreatic cancer trial
Amplia Therapeutics (ASX:ATX) is progressing thee Phase 2a stage of the ACCENT trial involvi...
via biotechdispatch.com.au
Amplia Therapeutics takes step up in pancreatic cancer treatment
Amplia Therapeutics (ASX:ATX) has progressed its ACCENT trial to evaluate narmafotinib, a drug that...
via themarketonline.com.au
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on p...
via stockhead.com.au
Powered by  
  • Company
    Amplia Therapeutics Ltd
  • Website
  • Sector
    Biotechnology
  • Industry
    Biotechnology
  • Code
    ASX:ATX
  • Socials
View Amplia Therapeutics Ltd's Profile

How do I invest?

Considering investing in Amplia Therapeutics Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:ATX

    On your online investment platform search for the stock ticker code ASX:ATX to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.

Up